Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter

28 de septiembre de 2018 actualizado por: Marvao Medical

Analysis of CRBSI (Catheter-Related Blood Stream Infection) Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter

A U.S. multi-centre post approval registry to analyse the CRBSI rate in patients with the NexSite HD Catheter for long term vascular access for hemodialysis.

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Descripción detallada

This is a U.S. multi - centre, prospective, non-randomized post approval registry. Approximately one hundred and twenty patients will be implanted with a NexSite HD catheter at four to eight U.S. sites where hemodialysis catheters are routinely implanted. Each site may enrol a maximum of 50 patients. Enrolled patients will be followed from device placement to device removal or 180 days post device placement. Patients will be enrolled once only.

The primary endpoint is CRBSI rate related to the NexSite HD catheter. Determination of infection will be decided by the investigator and if necessary adjudicated by the CEC (Clinical Events Committee) based on blood culture results, regardless of whether the catheter is removed.

Secondary endpoints for the study are

  • Successful placement and continued use of the NexSite HD device designed for use in patients requiring long term hemodialysis.
  • Healing of catheter exit site
  • Tunnel Infections
  • Exit site infections
  • Early non-infectious complications associated with CVCs
  • Late non-infectious complications associated with Central Venous Catheters

Tipo de estudio

Intervencionista

Inscripción (Actual)

120

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • North Carolina
      • Greenville, North Carolina, Estados Unidos, 27834
        • Eastern Nephrology Associates
      • New Bern, North Carolina, Estados Unidos, 28542
        • Eastern Nephology Associates
      • Raleigh, North Carolina, Estados Unidos, 27610
        • Capital Nephrology Associates
    • South Carolina
      • Orangeburg, South Carolina, Estados Unidos, 29118
        • South Carolina Nephrology and Hypertension Center Inc
    • Texas
      • Lubbock, Texas, Estados Unidos, 79416
        • Lubbock Vascular Access Centre
      • San Antonio, Texas, Estados Unidos, 78215
        • Renal Associates

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 80 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. The patient shall be 18 - 80 years old.
  2. The patient requires the placement of a long term tunnelled HD catheter for administration of hemodialysis.
  3. The patient has anticipated survival in excess of 90 days from the anticipated date of catheter placement.
  4. The patient has the ability to understand the research subject information and sign a written Informed Consent form which must be obtained prior to initiation of the study.
  5. The patient receives the catheter via the internal jugular or subclavian vein.
  6. All female patients of child bearing potential must complete a negative pregnancy test and will confirm that they are not breastfeeding.

Exclusion Criteria:

  1. The patient is participating in another IRB (Institutional Review Board) clinical trial, which modifies standard-of-care treatment and/or involves an investigational device or drug.
  2. The patient has a confirmed or suspected infection, bacteraemia or septicaemia.
  3. The patient's physiology is NOT suitable for placement of the NexSite device; this will include an examination of the anatomy at the proposed catheter exit site.
  4. The patient is known or suspected to have allergies to the materials used in the construction of the device.
  5. The patient has previously suffered from coagulation issues or has had vascular surgery at the proposed placement site.
  6. The patient has received radiation treatment at the proposed catheter placement site.
  7. The patient has severe chronic obstructive lung disease.
  8. The patient is pyretic within 72 hours (temperature ≥38o C or 100.4oF) prior to placement and/or has received antimicrobial drugs within two weeks prior to catheterisation.
  9. The patient is female of child bearing potential not using adequate contraception. (Adequate contraception is defined as abstinence, intrauterine device [IUD], birth control pills, or spermicidal gel with diaphragm or condom)
  10. The patient has another indwelling catheter.
  11. The patient has non-healing diabetic foot ulcers.
  12. The patient did not give informed consent.
  13. The patient would be unavailable for follow-up.
  14. The patient is a permanent nursing home resident.
  15. The proposed access site is not the internal jugular or subclavian vein.
  16. The patient is scheduled to undergo an elective surgical procedure (other than a procedure to create a graft or fistula) within the study timeframe.
  17. Any other condition that the Investigator believes should exclude the patient from the study.
  18. The patient does not have English or Spanish as their first language.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: NexSite HD Patients
NexSite HD patient catheter device placement
Measurement of CRBSI rate and other device related adverse events in patients with NexSite HD Catheter.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of participants with Catheter-Related Blood Stream Infection (CRBSI)(bacteremia/fungemia) as an adverse event.
Periodo de tiempo: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with a confirmed CRBSI for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of participants with adverse events associated with device placement and use.
Periodo de tiempo: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with adverse events associated with device placement and for the duration of catheter use or to 180 days post device placement.
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with unhealed catheter exit sites
Periodo de tiempo: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with unhealed exit sites for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with tunnel infection as an adverse event
Periodo de tiempo: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with a tunnel infection for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with exit site infection as an adverse event
Periodo de tiempo: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with a exit site infection for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with Pneumothorax, haemothorax, arrhythmia, air embolism or arterial perforation as an adverse event.
Periodo de tiempo: 1 day of device placement
Number of participants with non-infectious catheter complications within one day of placement.
1 day of device placement
Number of participants with Catheter dislodgement, Catheter tip dislodgement and catheter thrombosis as an adverse event.
Periodo de tiempo: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Number of participants with late non infectious complications for the duration of catheter use or to 180 days post device placement (whichever occurs first).
Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Jeffrey G Hoggard, MD, Capital Nephrology Associates

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de abril de 2015

Finalización primaria (Actual)

1 de septiembre de 2017

Finalización del estudio (Actual)

1 de julio de 2018

Fechas de registro del estudio

Enviado por primera vez

18 de mayo de 2015

Primero enviado que cumplió con los criterios de control de calidad

22 de mayo de 2015

Publicado por primera vez (Estimar)

25 de mayo de 2015

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

1 de octubre de 2018

Última actualización enviada que cumplió con los criterios de control de calidad

28 de septiembre de 2018

Última verificación

1 de septiembre de 2018

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • TR 0147

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre NexSite HD Patients

Suscribir